Thus, for ERα-positive BRCA1/2-related BC, chemoprevention, oophorectomy, and adjuvant treatment with selective estrogen receptor modulators or aromatase inhibitors to reduce risk of contralateral breast cancer are promising options. Here, CYP19A1 is linked to breast carcinoma.